临床试验中转化研究与相关性研究的统计学方面
Statistical aspect of translational and correlative studies in clinical trials.
作者信息
Pang Herbert, Wang Xiaofei
机构信息
School of Public Health, Li Ka Shing Faculty of Medicine, Pok Fu Lam, Hong Kong SAR, China.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
出版信息
Chin Clin Oncol. 2016 Feb;5(1):11. doi: 10.3978/j.issn.2304-3865.2014.07.04.
Abstract
In this article, we describe statistical issues related to the conduct of translational and correlative studies in cancer clinical trials. In the era of personalized medicine, proper biomarker discovery and validation is crucial for producing groundbreaking research. In order to carry out the framework outlined in this article, a team effort between oncologists and statisticians is the key for success.
摘要
在本文中，我们描述了与癌症临床试验中的转化研究和相关研究实施相关的统计学问题。在个性化医疗时代，恰当的生物标志物发现与验证对于开展开创性研究至关重要。为了实施本文概述的框架，肿瘤学家和统计学家之间的团队合作是成功的关键。
相似文献
1
Statistical aspect of translational and correlative studies in clinical trials.
Chin Clin Oncol. 2016 Feb;5(1):11. doi: 10.3978/j.issn.2304-3865.2014.07.04.
2
Key statistical concepts in cancer research.
Clin Adv Hematol Oncol. 2015 Mar;13(3):180-5.
3
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.
J Clin Endocrinol Metab. 2015 Dec;100(12):4387-95. doi: 10.1210/jc.2015-2818. Epub 2015 Sep 29.
4
Statistical issues in translational cancer research.
Clin Cancer Res. 2008 Oct 1;14(19):5954-8. doi: 10.1158/1078-0432.CCR-07-4537.
5
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
J Exp Clin Cancer Res. 2017 Dec 28;36(1):192. doi: 10.1186/s13046-017-0668-0.
6
Translating predictive biomarkers within oncology clinical development programs.
Biomark Med. 2015;9(9):851-62. doi: 10.2217/bmm.15.56. Epub 2015 Sep 2.
7
Emerging Biomarkers in the Era of Personalized Cancer Medicine.
Dis Markers. 2019 Aug 14;2019:5907238. doi: 10.1155/2019/5907238. eCollection 2019.
8
The clinical trials of the Organisation for Oncology and Translational Research (OOTR).
Int J Biol Markers. 2012 Dec 27;27(4):e353-6. doi: 10.5301/JBM.2012.10371.
9
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
Adv Exp Med Biol. 2015;867:81-90. doi: 10.1007/978-94-017-7215-0_6.
10
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Br Med Bull. 2015 Jun;114(1):17-27. doi: 10.1093/bmb/ldv011. Epub 2015 Apr 28.
引用本文的文献
1
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.
Lung Cancer. 2015 Nov;90(2):281-7. doi: 10.1016/j.lungcan.2015.08.007. Epub 2015 Aug 18.
本文引用的文献
1
Biomarker based clinical trial design.
Chin Clin Oncol. 2014 Sep;3(3):39. doi: 10.3978/j.issn.2304-3865.2014.02.03.
2
A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
Lancet Oncol. 2014 Apr;15(4):e184-93. doi: 10.1016/S1470-2045(13)70607-7.
3
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Ann Oncol. 2014 Apr;25(4):816-823. doi: 10.1093/annonc/mdu026.
4
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.
5
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.
Genet Epidemiol. 2013 Apr;37(3):276-82. doi: 10.1002/gepi.21721. Epub 2013 Mar 7.
6
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
PLoS Med. 2012;9(5):e1001216. doi: 10.1371/journal.pmed.1001216. Epub 2012 May 29.
7
Gene selection using iterative feature elimination random forests for survival outcomes.
IEEE/ACM Trans Comput Biol Bioinform. 2012 Sep-Oct;9(5):1422-31. doi: 10.1109/TCBB.2012.63.
8
Pathway-based identification of SNPs predictive of survival.
Eur J Hum Genet. 2011 Jun;19(6):704-9. doi: 10.1038/ejhg.2011.3. Epub 2011 Feb 2.
9
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
Pain Med. 2010 Mar;11(3):337-46. doi: 10.1111/j.1526-4637.2009.00774.x. Epub 2010 Jan 15.
10
Pathway analysis using random forests with bivariate node-split for survival outcomes.
Bioinformatics. 2010 Jan 15;26(2):250-8. doi: 10.1093/bioinformatics/btp640. Epub 2009 Nov 18.
Zotero 插件